Eden Research Share Discussion Threads

[supersonico] 30/3/2021 13:19

That's right POV...

I'm Glad you don't feel pressured like many do to keep tight lipped about some of the deception that goes on on these boards.

[neutralpov] 30/3/2021 13:04

I think the record of recent trades merits close examination.

The bid price is currently 14.5p but just try to sell more than 2500 and it drops dramatically.

U s e y o u r b r a i n z

[supersonico] 30/3/2021 12:56

Honestly no need to explain youself ..Erinvale

Much appreciated as I said..

I don't question your authenticity as I hope others will not either.

[ravenna23] 30/3/2021 12:01

Probably lucky on this occasion, but will never be touching an AIM share again due to lax public reporting requirements. This deficiency far outweighs any tax advantage. Just look at valuation to turnover ratio, and think.

[neutralpov] 30/3/2021 11:51

hahahaha!! ;D

[neutralpov] 30/3/2021 11:45

@ravenna23 30 Mar '21 - 10:18 - 8991
> Neutral POV that is not strictly true.

Hi.
But I made at least six separate assertions in my last post in this thread. Which of them, IYO, was "not strictly true"?
The one you appear to be disputing is re almost all PIs losing money in such hopeless stocks. But then you go on to agree that you were a happy exception and that "they do say that 99% of traders lose money." Doesn't sound like you are disagreeing. ;-)


@spadeychops 30 Mar '21 - 09:59 - 8990
Another one of the multi-avatars pops up?

Amateurs.... settling down with the popcorn, researching how I can best short this dog of a share.

[erinvale1] 30/3/2021 08:21

Supersonico, I have been involved to various degrees with Eden since Ximed days and seen its serial management ineptitude. Invariably, consultants and ‘deals’ have been taken as progress and as a substitute for sales. As I have repeatedly said, Eden has world-class (much overused term) IP but, despite annual promises of ‘transformation’, has failed to capitalise on what it owns. If a Corteva deal is struck, which is greatly to be hoped but by no means certain, this could transform Eden’s fortunes. I am sanguine on this. My bet - and I would be delighted to be proved wrong - is that Eden will slide further downwards unless a deal is struck soon.

[supersonico] 30/3/2021 07:31

Thanks for caring Erinvale.

It is a rarely seen quality on these boards.

I just hope everyone is not writing your concerns off as agenda based but instead seeing compassion and love for fellow investors as your only motivation.

Much appreciated. xxx

[investingisatrickygame] 29/3/2021 21:29

To anyone absorbing the negative posts from NeutralPOV and erinvale1 I would suggest you read today's posts by attyg, numbers 8974 and 8977 which paint a far more accurate picture of the position Eden finds itself in today, regardless of where it was in the past.

Circumstances change, boardrooms change and this is, in my opinion, the reality of where we are right now.

To those moaning, sell, I'm confident, as is attyg, that you will soon regret it.

[erinvale1] 29/3/2021 19:11

Eden has been appallingly badly managed under Sean Smith. Lousy PR/RNS, no significant sales and money flying out on offices, labs and consultants who were brought in to turn the company around. I agree with Neutral POV - sell before Eden collapses.

[chrischas] 29/3/2021 19:07

Well if Eden dont inform the market in which they are in: 2 directors have been substantially " underperforming ".Then,they could be in a lot of trouble in the medium to long term.

[neutralpov] 29/3/2021 18:09

Amend::

EDEN RESEARCH plc (EDEN.L) ... Very strong SELL recommendation.
DYOR, YMMV, TINIA.

[investingisatrickygame] 29/3/2021 16:34

Super, maybe BGF sold or perhaps that put that stock into another fund of theirs, if they have one.

[supersonico] 29/3/2021 14:49

BGF Investment Management Limited

Now hold 14.962% Down From 15.337%

[investingisatrickygame] 29/3/2021 14:14

AttyG

As per your posts, it is clear to anyone reading that Eden has directed investors towards a deal with Corteva that has wider geography, more crops and greater value than first RNS'd. Whilst Eden can still be opaque, these three elements cannot be in dispute if you read the information Eden has posted.

This as you say, would also account for why we are still waiting for a MORE THAN positive RNS which should transform both the Company and its share price.

So in my opinion, if you're holding, continue to do so and if you're of a mind to invest more and can afford to do so, it looks very much to me as though circumstances are in your favour (price, timing and ROI in the very short, medium and long term)

[supersonico] 29/3/2021 13:04

AttyG,
Perhaps I should have said Parallel Parallel Consolidator delay.

Corteva/ Bayer / BASF / SYNGENTA / UPL / Sumitomo / Dow.

AWGATWT.

[attyg] 29/3/2021 11:59

Now super, you are not alluding to the prospect of Eden coming to an arrangement with another company in addition to Corteva?
Were you looking at slide 16 in the 11 May 2020 Presentation where Eden compares itself (Mkt Cap £15m) with its competitors, Syngenta, BASF, Bayer and Marrone with Mkt Caps $41b, $62b, $71b and $140m and in which Eden has ticks in all the important boxes and only Maronne compares, but not in efficacy ie does not do the job, well.
Are you suggesting one of these majors could be interested in what Eden has to offer?

[supersonico] 29/3/2021 10:42

In short expect Parallel Parallel delays.

[investingisatrickygame] 27/3/2021 23:42

11/2/2021 - RNS - Year-End Trading Update

Under the heading, 'Corteva'

At the beginning of 2020, Eden signed a one-year exclusive Evaluation Agreement with Corteva. Corteva (NYSE: CTVA) is the fourth largest agriculture input company in the world and is a publicly traded, pure-play agriculture company created by the combination of DuPont Crop Protection, DuPont Pioneer seeds and Dow AgroSciences. This agreement allowed Corteva time to exclusively evaluate Eden's Sustaine® encapsulation technology and several formulations in specific seed treatment applications. If successful, it was anticipated that this would lead to Corteva being granted exclusive distribution rights, on terms to be negotiated, initially targeting several major crops, including broad acre crops.

This process is currently moving forward, as expected, and the Company will provide an update as soon as practicable.

This represents Eden's first collaborative development efforts in the area of seed treatments as well as the first disclosed collaboration with a global leader in agricultural inputs. Additionally, this is the most comprehensive work done by to date on major broad-acre crops using Eden's technologies.